Literature DB >> 23712746

Genetic susceptibility variants associated with colorectal cancer prognosis.

Anna Abulí1, Juan José Lozano, María Rodríguez-Soler, Rodrigo Jover, Xavier Bessa, Jenifer Muñoz, Clara Esteban-Jurado, Ceres Fernández-Rozadilla, Angel Carracedo, Clara Ruiz-Ponte, Joaquín Cubiella, Francesc Balaguer, Luis Bujanda, Josep M Reñé, Juan Clofent, Juan Diego Morillas, David Nicolás-Pérez, Rosa M Xicola, Xavier Llor, Josep M Piqué, Montserrat Andreu, Antoni Castells, Sergi Castellví-Bel.   

Abstract

Colorectal cancer (CRC) is the second leading cause of cancer-related death among men and women in Western countries. Once a tumour develops, a differentiated prognosis could be determined by lifestyle habits or inherited and somatic genetic factors. Finding such prognostic factors will be helpful in order to identify cases with a shorter survival or at a higher risk of recurrence that may benefit from more intensive treatment and follow-up surveillance. Sixteen CRC genetic susceptibility variants were directly genotyped in a cohort of 1235 CRC patients recruited by the EPICOLON Spanish consortium. Univariate Cox and multivariate regression analyses were performed taking as primary outcomes overall survival (OS), disease-free survival and recurrence-free interval. Genetic variants rs9929218 at 16q22.1 and rs10795668 at 10p14 may have an effect on OS. The G allele of rs9929218 was linked with a better OS [GG genotype, genotypic model: hazard ratio (HR) = 0.65, 95% confidence interval (CI) 0.45-0.93, P = 0.0179; GG/GA genotypes, dominant model: HR = 0.66, 95% CI 0.47-0.94, P = 0.0202]. Likewise, the G allele of rs10795668 was associated with better clinical outcome (GG genotype, genotypic model: HR = 0.73, 95% CI 0.53-1.01, P = 0.0570; GA genotype, genotypic model: HR = 0.66, 95% CI 0.47-0.92, P = 0.0137; GG/GA genotypes, dominant model: HR = 0.68, 95% CI 0.50-0.94, P = 0.0194). In conclusion, CRC susceptibility variants rs9929218 and rs10795668 may exert some influence in modulating patient's survival and they deserve to be further tested in additional CRC cohorts in order to confirm their potential as prognosis or predictive biomarkers.

Entities:  

Mesh:

Year:  2013        PMID: 23712746     DOI: 10.1093/carcin/bgt179

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  13 in total

1.  A subset of genetic susceptibility variants for colorectal cancer also has prognostic value.

Authors:  S Noci; M Dugo; F Bertola; F Melotti; A Vannelli; T A Dragani; A Galvan
Journal:  Pharmacogenomics J       Date:  2015-05-12       Impact factor: 3.550

2.  A genome-wide search for determinants of survival in 1926 patients with advanced colorectal cancer with follow-up in over 22,000 patients.

Authors:  Christopher Wills; Yazhou He; Matthew G Summers; Yi Lin; Amanda I Phipps; Katie Watts; Philip J Law; Nada A Al-Tassan; Timothy S Maughan; Richard Kaplan; Richard S Houlston; Ulrike Peters; Polly A Newcomb; Andrew T Chan; Daniel D Buchanan; Steve Gallinger; Loic L Marchand; Rish K Pai; Qian Shi; Steven R Alberts; Victoria Gray; Hannah D West; Valentina Escott-Price; Malcolm G Dunlop; Jeremy P Cheadle
Journal:  Eur J Cancer       Date:  2021-11-15       Impact factor: 10.002

3.  Metformin inhibited colitis and colitis-associated cancer (CAC) through protecting mitochondrial structures of colorectal epithelial cells in mice.

Authors:  Shu-Qing Wang; Shu-Xiang Cui; Xian-Jun Qu
Journal:  Cancer Biol Ther       Date:  2018-10-25       Impact factor: 4.742

4.  Analyses of 7,635 Patients with Colorectal Cancer Using Independent Training and Validation Cohorts Show That rs9929218 in CDH1 Is a Prognostic Marker of Survival.

Authors:  Christopher G Smith; David Fisher; Rebecca Harris; Timothy S Maughan; Amanda I Phipps; Susan Richman; Matthew Seymour; Ian Tomlinson; Dan Rosmarin; David Kerr; Andrew T Chan; Ulrike Peters; Polly A Newcomb; Shelley Idziaszczyk; Hannah West; Angela Meade; Richard Kaplan; Jeremy P Cheadle
Journal:  Clin Cancer Res       Date:  2015-04-14       Impact factor: 12.531

5.  A retrospective observational study of the relationship between single nucleotide polymorphisms associated with the risk of developing colorectal cancer and survival.

Authors:  Eva J A Morris; Steve Penegar; Nicola Whiffin; Peter Broderick; D Timothy Bishop; Emma Northwood; Philip Quirke; Paul Finan; Richard S Houlston
Journal:  PLoS One       Date:  2015-02-24       Impact factor: 3.240

Review 6.  Genetic Variability as a Regulator of TLR4 and NOD Signaling in Response to Bacterial Driven DNA Damage Response (DDR) and Inflammation: Focus on the Gastrointestinal (GI) Tract.

Authors:  Evagelia Spanou; Polyxeni Kalisperati; Ioannis S Pateras; Alexandros Papalampros; Alexandra Barbouti; Athanasios G Tzioufas; Athanassios Kotsinas; Stavros Sougioultzis
Journal:  Front Genet       Date:  2017-05-29       Impact factor: 4.599

Review 7.  Toll-like receptor 4 gene polymorphisms and susceptibility to colorectal cancer: a meta-analysis and review.

Authors:  Wang Yan Sheng; Zhang Yong; Zhu Yun; Hu Hong; Luo Lin Hai
Journal:  Arch Med Sci       Date:  2015-08-11       Impact factor: 3.318

8.  Polymorphism of DNA Methyltransferase 3b and Association with Development and Prognosis in Gastric Cancer.

Authors:  Chuan Wang; Zhifang Jia; Donghui Cao; Lili You; Meishan Jin; Xing Wu; Simin Wen; Xueyuan Cao; Jing Jiang
Journal:  PLoS One       Date:  2015-08-11       Impact factor: 3.240

9.  Single nucleotide polymorphisms associated with colorectal cancer susceptibility and loss of heterozygosity in a Taiwanese population.

Authors:  Chih-Yung Yang; Ruey-Hwa Lu; Chien-Hsing Lin; Chih-Hung Jen; Chien-Yi Tung; Shung-Haur Yang; Jen-Kou Lin; Jeng-Kai Jiang; Chi-Hung Lin
Journal:  PLoS One       Date:  2014-06-26       Impact factor: 3.240

10.  Nucleotide variants of the cancer predisposing gene CDH1 and the risk of non-syndromic cleft lip with or without cleft palate.

Authors:  Kamil K Hozyasz; Adrianna Mostowska; Piotr Wójcicki; Agnieszka Lasota; Barbara Offert; Adam Balcerek; Izabella Dunin-Wilczyńska; Paweł P Jagodziński
Journal:  Fam Cancer       Date:  2014-09       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.